Insilico Medicine IP Ltd. has divulged serine/threonine-protein salt-inducible kinase (SIK) inhibitors reported to be useful for the treatment of autoimmune disease, cancer, metabolic diseases, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results